ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company announces that it has been informed by Simbec-Orion, the contract research organisation conducting our Lupuzor™ pivotal Phase III trial study, that ‘database lock’ is expected on 6 April 2018 with top line results announced by mid-April 2018. Lupuzor™ is the Company’s lead programme for the…

ImmuPharma PLC (LSE: IMM), specialist drug discovery and development company, is pleased to announce that Tim McCarthy, Chairman, will be presenting at an investor evening hosted by Turner Pope Investments (TPI) Ltd. TPI acted as agent in the recent successful £10 million fundraise by ImmuPharma. The event will be held on Monday 26th February 2018…

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company, announces that on 8 February 2018 it received notification that Alto Invest no longer holds a notifiable interest in the Company. This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, has received notification that Lanstead Capital LP (“Lanstead”) has confirmed an increase in its holding in ImmuPharma. Lanstead now holds 6,985,893 Ordinary shares of 10p each in the Com-pany, representing 5.01% of ImmuPharma’s issued share capital of 139,467,430 Ordinary shares with voting rights. This announcement…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that, in response to institutional demand, it has completed a fundraise totalling £10 million (before expenses) via a placing of 6,944,445 new ordinary shares of 10p each in the Company (“Ordinary Shares”) at a price of 144p per share (the “Placing…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to confirm that the ongoing 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, is now complete, following the last patient having attended their final assessment. Final patient data from the trial are…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide an update of its pivotal 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. Study summary as at 1st November 2017 • 200 patients successfully recruited…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, has received notification that Alto Invest now holds 5,242,536 ordinary shares of 10p each in the Company, representing 3.96% of the Company’s issued share capital with voting rights. This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

ImmuPharma plc (LSE: IMM), the specialist drug discovery and development company, wishes to announce the completion of the Sharing Agreement entered into with Lanstead Capital L.P. (‘Lanstead’) in February 2016 (“Sharing Agreement”). As announced on 5 February 2016, Lanstead subscribed for £4.4 million of new ordinary shares in ImmuPharma, with both parties also entering into…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2017 (the “Period”). Key Highlights Lupuzor™: is the Company’s lead program for the potential breakthrough compound for Lupus a potential life threatening auto-immune disease • Total 11…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to confirm a further update on Lupuzor™ its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. On 21 September 2017 ImmuPharma announced that that all patients in the Company’s pivotal Phase III Lupuzor™ study had passed the…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide an update of its pivotal 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. Study summary as at 15th September 2017 • 200 patients successfully recruited…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed.

Update on Lupuzor™ Pivotal Phase III Study A video of the presentation will be available to view on the Company’s website from Monday 3 July 2017 at www.immupharma.co.uk/events/2017 Download the June 2017 IMM presentation

Notice of Annual General Meeting on 30 June 2017 at 10.30am Investor presentation to follow at 11.30am Venue: Sky Light City, 50 Basinghall Sreet, London, EC2 ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company confirms that today the Annual Report and Accounts for the year ended 31 December 2016…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2016 (the “Period”). Key Highlights (including post Period review) Lupuzor™: is the Company’s lead program for the potential breakthrough compound for lupus a potential life threatening auto-immune…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, confirms that it will be announcing its full year results for the year ended 31 December 2016 on Thursday 1 June 2017.

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide an update of its pivotal 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. Study Summary 200 patients successfully recruited and randomised (dosed) 7 Countries and…

ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that it has received notification by Legal & General Group Plc (“L&G”) confirming its holding in ImmuPharma of  4,446,545 million Ordinary Shares in the capital of the Company, representing 3.35% of ImmuPharma’s total voting rights figure of  132,522,985 Ordinary Shares.…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that further to the announcement made earlier today entitled “Accelerated Bookbuild for the Issue of Equity”, the accelerated Bookbuild, which was oversubscribed, has now closed. The Company has raised a total of £4.1 million (before expenses) by way of an issue…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce a proposed placing, raising a minimum of £3 million (before expenses), via the issue of new ordinary shares of 10p each (“Ordinary Shares”) to new and existing investors (the “New Share Placing”). The New Share Placing will provide ImmuPharma with additional…